A validated index for breast cancer that quantifies individual risk for late recurrence was associated with a substantial reduction in the use of adjuvant hormone therapy in a prospective study.
“Physicians typically recommend adjuvant hormonal therapy for most women with breast cancer, but a substantial proportion of women have a low risk for a recurrence and are unlikely to benefit,” explained Tara Sanft, MD, medical director of adult survivorship at the Yale Cancer Center Survivorship Clinic in New Haven, Connecticut. “We wanted to test the ability of this assay to alter treatment decisions in the context of its effect on patient satisfaction with the decision process.”
Information generated by the Breast Cancer Index (BCI), which is commercially available (bioTheranostics, San Diego, CA), led to a change in treatment decision in 27% of patients, according to data presented at the 2015 ASCO Annual Meeting. In most cases, the change was the decision to discontinue adjuvant hormonal therapy based on the evidence of a low risk of recurrence.
The study enrolled 100 women with stage I to III breast cancer, who had completed 3.5 years of endocrine therapy. Prior to performing the BCI assay, which yields a composite score for a patient’s risk of a late distant recurrence based on an algorithmic combination of molecular signaling pathways and gene mutations, patients and their physicians were asked to estimate their risk of recurrence. Patients also completed the State Trait Anxiety Inventory (STAI) and the Decisional Conflict Scale (DCS) prior and then again after the BCI assay results were available.
Most of the participants were white and postmenopausal. The median age was 60.5 years. More than 90% of patients had stage I (58%) or stage II (33%) cancers, and nearly 90% were HER2 negative. The majority of breast cancers at the time of diagnosis (65%) were 2 cm or smaller in size, with almost all of the rest no larger than 5 cm. Most women (70%) also had node-negative disease. Endocrine therapy at the time of testing was an aromatase inhibitor (66%) or tamoxifen (34%).
The objective assessment of recurrence risk provided by the BCI assay, which has been validated in a series of prospective, randomized trials, differed from both patient and physician estimates of risk. According to the BCI, 59% of patients were at low risk of a recurrence, 24% were at intermediate risk, and 17% were at high risk. Physician estimates for these risk categories were 49%, 33%, and 18%, respectively. The distribution of risks as estimated by patients, responding to terms “not at all likely,” “somewhat likely,” and “very likely,” were 24%, 71%, and 1%, respectively.
The large proportion of patients who placed themselves in the intermediate group is reflective of uncertainty that might drive a preference for treatment even when the likelihood of benefit is low. The advantage of the BCI, according to Sanft, is that it provides both an objective estimate of risk as well as an estimate of likelihood of benefit from extended adjuvant therapy. Together, these provide an important level of reassurance to both physicians and patients about how to proceed with treatment.
This reassurance was reflected by change in the STAI and DCS scores among patients before and after the BCI results were made available. According to Sanft, anxiety scores were reduced by 50% (P= .003) on STAI, while decisional conflict scores were reduced by 53% (P<.001) on DCS.
“Several studies have associated extended endocrine therapy with a reduced risk of breast cancer, but the absolute benefit is modest and extended treatment is not without toxicity,” Sanft reported. “These data suggest that BCI allows individualized treatment while reducing anxiety and improving patient satisfaction.”
Sanft TB, Aktas B, Schroeder B, et al. Prospective study of the decision-making impact of the breast cancer index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Presented at the ASCO Annual Meeting: May 30, 2015. Abstract # 538.
<<<
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More